Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06548321
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
Benefits of Extracorporeal Shockwave Therapy to Reduce Spasticity in StrokeCP
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Benefits of Extracorporeal Shockwave Therapy to Reduce Spasticity in StrokeCP
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Study will help to explain us that ExtracorporealShockwave therapy can reduce spasticity in Stroke Patienthelp them to restore their abilities and ROMTherapy reduces dependency rate of patientAlso seen this therapy shows reduction in spasticity of CP child populationImproving the motor recovery
Detailed Description:
ESWT therapy increses molecular and immunological reactionsincrease blood microcirculation and neurovascularizationIt enhancing the neural proliferation of neural stem cellNSCwhich shows repair in brain function in CNS diseasesExtracorporeal shockwave can produce Nitric oxide in enzymatic and non enzymatic way which help to reduce muscle spasmExtracorporeal Shockwave reduce the exitibilty of motor neuron by vibratory stimulation of tendon and reduces tensionAfter 2 weeks ESWT muscle tension reduces increases range of motion reduces the painshock wave therapy appears to be effective in reducing spasticity levels irrespective of the age of the participants the type of injury and the tool used to measure the effectESWT change in motor neuron exitibilty also associated with the spastic muscle
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None